{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:01:47Z","timestamp":1773302507835,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116584","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:27:28Z","timestamp":1771288048000},"page":"116584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6124-6616","authenticated-orcid":false,"given":"Sidsel","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotte B.","family":"Colmorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-9232","authenticated-orcid":false,"given":"Eva","family":"Ellebaek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1194-8393","authenticated-orcid":false,"given":"Stine Gry","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-273X","authenticated-orcid":false,"given":"Christina","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-9281","authenticated-orcid":false,"given":"Troels Holz","family":"Borch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Donia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5383-5501","authenticated-orcid":false,"given":"Jens","family":"Fedder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten T.","family":"Macklon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7378","key":"10.1016\/j.ejca.2026.116584_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"10304","key":"10.1016\/j.ejca.2026.116584_bib2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2026.116584_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"October","key":"10.1016\/j.ejca.2026.116584_bib4","article-title":"Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies","volume":"195","author":"Schina","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116584_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","author":"Blank","year":"2024","journal-title":"N Engl J Med Publ Online"},{"key":"10.1016\/j.ejca.2026.116584_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","author":"Schmid","year":"2024","journal-title":"N Engl J Med Publ Online"},{"issue":"19","key":"10.1016\/j.ejca.2026.116584_bib7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116584_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116584_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115053","article-title":"Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 \u2013 Seasonal variation and association with outcome","author":"Jurlander","year":"2024","journal-title":"Eur J Cancer Publ Online"},{"issue":"36","key":"10.1016\/j.ejca.2026.116584_bib10","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116584_bib11","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: An update","volume":"12","author":"Fletcher","year":"2024"},{"issue":"5","key":"10.1016\/j.ejca.2026.116584_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100276","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ejca.2026.116584_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines12092106","article-title":"The effects of cancer immunotherapy on fertility: focus on Hematological malignancies","volume":"12","author":"Caserta","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ejca.2026.116584_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.rbmo.2021.09.004","article-title":"Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction","volume":"44","author":"Bussies","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ejca.2026.116584_bib15","article-title":"Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy","volume":"6","author":"Hassel","year":"2021"},{"key":"10.1016\/j.ejca.2026.116584_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2021.08.044","article-title":"Adjuvant treatment for melanoma in clinical practice \u2013 Trial versus reality","volume":"158","author":"de Meza","year":"2021","journal-title":"Eur J Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2026.116584_bib17","doi-asserted-by":"crossref","first-page":"12013","DOI":"10.1200\/JCO.2023.41.16_suppl.12013","article-title":"Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial","volume":"41","author":"Buchbinder","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116584_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-025-07702-w","article-title":"Impact of pembrolizumab on ovarian function in young triple - negative breast cancer patients treated with chemo - immunotherapy","volume":"212","author":"Perdrix","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.ejca.2026.116584_bib19","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.ccell.2024.10.005","article-title":"Fertility outcomes post immune checkpoint inhibitor exposure","volume":"42","author":"Harrold","year":"2024","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ejca.2026.116584_bib20","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdw696","article-title":"Immune checkpoint inhibitors-related orchitis","volume":"28","author":"Brunet-Possenti","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116584_bib21","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1634\/theoncologist.2018-0722","article-title":"Severe epididymo-orchitis and encephalitis complicating anti-PD-1 therapy","volume":"24","author":"Quach","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejca.2026.116584_bib22","article-title":"Female oncofertility and immune checkpoint blockade in melanoma: where are we today","volume":"17","author":"Lee","year":"2025","journal-title":"Cancers Multidiscip Digit Publ Inst (MDPI)"},{"issue":"3","key":"10.1016\/j.ejca.2026.116584_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13649","article-title":"Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube","volume":"89","author":"Johnson","year":"2023","journal-title":"Am J Reprod Immunol"},{"issue":"7528","key":"10.1016\/j.ejca.2026.116584_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116584_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coemr.2020.12.004","article-title":"Evaluating the impacts of emerging cancer therapies on ovarian function","volume":"18","author":"Alesi","year":"2021","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"8","key":"10.1016\/j.ejca.2026.116584_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116584_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12094-021-02699-2","article-title":"Multidisciplinary consensus on the criteria for fertility preservation in cancer patients","volume":"24","author":"Santaballa","year":"2022","journal-title":"Clin Transl Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:27:36Z","timestamp":1773235656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926003643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"alternative-id":["S0959804926003643"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116584","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116584"}}